Progyny shares are trading lower after the company reported worse-than-expected Q2 revenue results. Also, Leerink Partners downgraded the stock from Outperform to Market Perform and lowered its price target from $31 to $25.
Portfolio Pulse from Benzinga Newsdesk
Progyny shares are trading lower after the company reported worse-than-expected Q2 revenue results. Additionally, Leerink Partners downgraded the stock from Outperform to Market Perform and lowered its price target from $31 to $25.
August 07, 2024 | 11:40 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Progyny shares are trading lower due to disappointing Q2 revenue results and a downgrade from Leerink Partners, which also lowered its price target from $31 to $25.
The combination of worse-than-expected Q2 revenue results and a downgrade from a reputable analyst firm is likely to negatively impact Progyny's stock price in the short term. The lowered price target further underscores the negative sentiment.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100